Shamriz Oded, Parnasa Elchanan, Rubin Limor, Talmon Aviv, Ribak Yaarit, Hindi Isaam, Peleg Hagit, Confino-Cohen Ronit, Tal Yuval
Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
BMC Immunol. 2025 Apr 8;26(1):29. doi: 10.1186/s12865-025-00705-8.
Physicians may encounter situations where they need to co-administer omalizumab with non-IgE-targeting monoclonal antibodies. In this study, we share our experience with these dual biologic treatments.
To evaluate the efficacy and safety of dual biological therapy using omalizumab and non-IgE-targeting monoclonal antibodies at a single center.
We retrospectively reviewed the medical records of adults treated with a dual biological therapy regimen consisting of omalizumab and another biologic between 2020 and 2022.
Our review identified nine patients (age range: 51-75 years, 7 women and 2 men) who were treated with omalizumab for high Th2 disorders, including chronic spontaneous urticaria (n = 7) and asthma (n = 2). Seven patients received a second biologic for co-existing non-Th2 disorders, while two received an additional biologic to better control their Th2-mediated disorders. The patients were treated with the following biologics: anti-IL-5 agents (mepolizumab [n = 1] and benralizumab [n = 1]), the IL-4/13 inhibitor dupilumab (n = 1), the anti-IL-17 biologic secukinumab (n = 1), the IL-1 inhibitor anakinra (n = 1), the anti-calcitonin gene-related peptide agent fremanezumab (n = 1), and anti-TNF-α agents (etanercept [n = 1], golimumab [n = 1], and adalimumab [n = 1]). Dual biotherapy was administered for 3-34 months with observed clinical improvement. No adverse events or infections were reported.
Dual biological treatment with omalizumab and another biologic appears to be safe, with no need to discontinue non-IgE-targeting agents during omalizumab therapy.
医生可能会遇到需要将奥马珠单抗与非IgE靶向单克隆抗体联合使用的情况。在本研究中，我们分享了我们在这些双重生物治疗方面的经验。
在单一中心评估使用奥马珠单抗和非IgE靶向单克隆抗体的双重生物治疗的疗效和安全性。
我们回顾性分析了2020年至2022年间接受由奥马珠单抗和另一种生物制剂组成的双重生物治疗方案的成年患者的病历。
我们的回顾确定了9名患者（年龄范围：51 - 75岁，7名女性和2名男性），他们因高Th2疾病接受奥马珠单抗治疗，包括慢性自发性荨麻疹（n = 7）和哮喘（n = 2）。7名患者因并存的非Th2疾病接受了第二种生物制剂治疗，而2名患者接受了额外的生物制剂以更好地控制其Th2介导的疾病。患者接受了以下生物制剂治疗：抗IL - 5药物（美泊利单抗[n = 1]和贝那利珠单抗[n = 1]）、IL - 4/13抑制剂度普利尤单抗（n = 1）、抗IL - 17生物制剂司库奇尤单抗（n = 1）、IL - 1抑制剂阿那白滞素（n = 1）、抗降钙素基因相关肽药物夫雷西尤单抗（n = 1）以及抗TNF - α药物（依那西普[n = 1]、戈利木单抗[n = 1]和阿达木单抗[n = 1]）。双重生物治疗持续3 - 34个月，观察到临床症状改善。未报告不良事件或感染。
奥马珠单抗与另一种生物制剂的双重生物治疗似乎是安全的，在奥马珠单抗治疗期间无需停用非IgE靶向药物。
